sorry but IMHO this looks like an overblown announcement -they’re trumpeting a “breakthrough” on the basis of what? An unspecified target that hasn’t even gone into preclinical testing yet. there’s big attrition from ID to preclinical to clinical phase1 so higher chance it’ll fail ••might be better to treat with some healthy scepticism until this hits phase 1 at earliest or market sees some evidence of this “breakthrough” in a peer review publication. just my opinion DYOR
NOX Price at posting:
51.0¢ Sentiment: None Disclosure: Not Held
